Navigation Links
AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Date:11/24/2009

partial or complete tumor responses according to Response Evaluation Criteria in Solid Tumors (RECIST) and/or Gynaecologic Cancer Intergroup (GCIG) guidelines. Secondary endpoints include time to progression, survival, toxicity as well as adverse effects.

About Endometrial and Ovarian Cancer

Cancer of the endometrium is the most common gynaecologic malignancy and accounts for 6% of all cancers in women. The majority of the cases occur in postmenopausal women, with the largest number of women developing their cancers during their sixth decade. Approximately 38,000 new cases and 9,000 deaths from this disease are estimated annually in Europe (Source: Annals of Oncology 2004; 15:1149-50).

Ovarian cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnoses in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year (Source: Gynaecologic Oncology 2004; 92:819-26).

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , BRISBANE, Calif., Aug. 6 ... the second quarter and six months ended June 30, 2009. ... million, or $0.81 per share, compared with a net loss of $29.6 million, ... , Dan Welch, Chairman, Chief Executive Officer and President of ...
... , EMERYVILLE, Calif., Aug. 6 ... John E. Sealander, AIA, ACHA, NCARB, LEED(R) AP, as a ... http://www.ratcliffarch.com ) provides a broad array ... clients throughout the Western United States. , , ...
... LEXINGTON, Ky. , Aug. 6 ... announced today that its scientists and collaborators from the Medical ... rat model of severe combined immunodeficiency, or SCID. The Transposagen ... of the immune system. Transposagen will be marketing SCID rats ...
Cached Biology Technology:InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 3InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 4InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 5InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 6InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 7InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 8InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 9InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 10InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 11InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 12InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 14InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 15Ratcliff Adds Architect John Sealander to Healthcare Practice Group 2Transposagen Creates a Rat Model of the Human Immune System 2Transposagen Creates a Rat Model of the Human Immune System 3
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... including scientists from Woods Hole Oceanographic Institution (WHOI), discovered ... Until now, sea ice was thought to block sunlight ... under the ice. The amount of phytoplankton growing ... the amount found in neighboring ice-free waters. The bloom ...
... exploring how proteins interact with crucial DNA sequences to ... biological events that may eventually be manipulated to provide ... regulatory elements in DNA called promoters and enhancers communicate ... over large genomic distances, hundreds of thousands of chemical ...
... Institute for the Environment researchers have helped open a new ... world,s coral reefs. Working with an international team, the ... Rob Dunbar and Steve Monismith found a way to ... Great Barrier Reef. The water inside the device can mimic ...
Cached Biology News:Scientists discover huge phytoplankton bloom in ice-covered waters 2Scientists discover huge phytoplankton bloom in ice-covered waters 3Manipulating chromatin loops to regulate genes may offer future treatments for blood diseases 2Stanford researchers help predict the oceans of the future with a mini-lab 2
... derivatives that have mutations in both the ... genes, which greatly enhances disulfide bond formation ... expression in Origami(DE3) yielded 10-fold more active ... overall expression levels were similar (1). Origami ...
Request Info...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
Biology Products: